keyword
https://read.qxmd.com/read/38503896/synthetic-dual-co-stimulation-increases-the-potency-of-hit-and-tcr-targeted-cell-therapies
#1
JOURNAL ARTICLE
Anton Dobrin, Pieter L Lindenbergh, Yuzhe Shi, Karlo Perica, Hongyao Xie, Nayan Jain, Andrew Chow, Jedd D Wolchok, Taha Merghoub, Michel Sadelain, Mohamad Hamieh
Chimeric antigen receptor T cells have dramatically improved the treatment of hematologic malignancies. T cell antigen receptor (TCR)-based cell therapies are yet to achieve comparable outcomes. Importantly, chimeric antigen receptors not only target selected antigens but also reprogram T cell functions through the co-stimulatory pathways that they engage upon antigen recognition. We show here that a fusion receptor comprising the CD80 ectodomain and the 4-1BB cytoplasmic domain, termed 80BB, acts as both a ligand and a receptor to engage the CD28 and 4-1BB pathways, thereby increasing the antitumor potency of human leukocyte antigen-independent TCR (HIT) receptor- or TCR-engineered T cells and tumor-infiltrating lymphocytes...
March 19, 2024: Nature Cancer
https://read.qxmd.com/read/38262306/the-side-effect-registry-immuno-oncology-serio-a-tool-for-systematic-analysis-of-immunotherapy-induced-side-effects
#2
JOURNAL ARTICLE
Carolin Ertl, Theresa Ruf, Dirk Mentzer, Mingzi Kong, Rafaela Kramer, Michael von Bergwelt-Baildon, Marion Subklewe, Dirk Tomsitz, Paolo A Ascierto, Reinhard Dummer, Helen Gogas, Celeste Lebbé, Georgina V Long, Grant McArthur, Tomas G Neilan, Antoni Ribas, Caroline Robert, Dirk Schadendorf, Lisa Zimmer, Thomas Eigentler, Stephan Grabbe, Andrea Forschner, Katharina C Kähler, Valeria Milani, Claudia Pföhler, Jessica Hassel, Ralf Gutzmer, Carmen Loquai, Bertrand Routy, Andrew J S Furness, Christian Blank, Jedd D Wolchok, Lars E French, Axel Hauschild, Lucie Heinzerling
BACKGROUND: Immunotherapies such as immune checkpoint inhibitors (ICI) are effective in multiple tumor entities but induce a plethora of side effects. Comprehensive real-world analyses are essential to identify new signals, characterize diagnostic features, enable risk assessment, determine pathomechanisms, assess effectiveness of side effect management and compare tumor outcomes. METHODS: The international online `Side-Effect Registry Immuno-Oncology´ (SERIO; www...
March 2024: European Journal of Cancer
https://read.qxmd.com/read/37930123/phase-ib-trial-of-phenformin-in-patients-with-v600-mutated-melanoma-receiving-dabrafenib-and-trametinib
#3
JOURNAL ARTICLE
Paul B Chapman, Mark Klang, Michael A Postow, Alexander N Shoushtari, Ryan J Sullivan, Jedd D Wolchok, Taha Merghoub, Sadna Budhu, Phillip Wong, Margaret K Callahan, Bin Zheng, Jonathan H Zippin
PURPOSE: Preclinical studies show that activation of AMP kinase by phenformin can augment the cytotoxic effect and RAF inhibitors in BRAF V600-mutated melanoma. We conducted a phase Ib dose-escalation trial of phenformin with standard dose dabrafenib/trametinib in patients with metastatic BRAF V600-mutated melanoma. PATIENTS AND METHODS: We used a 3+3 dose escalation design which explored phenformin doses between 50 mg and 200 mg bid. Patients also received standard dose dabrafenib/trametinib...
November 6, 2023: Cancer Res Commun
https://read.qxmd.com/read/37891002/apr-246-increases-tumor-antigenicity-independent-of-p53
#4
JOURNAL ARTICLE
Judith Michels, Divya Venkatesh, Cailian Liu, Sadna Budhu, Hong Zhong, Mariam M George, Daniel Thach, Zhong-Ke Yao, Ouathek Ouerfelli, Hengrui Liu, Brent R Stockwell, Luis Felipe Campesato, Dmitriy Zamarin, Roberta Zappasodi, Jedd D Wolchok, Taha Merghoub
We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly. MQ treatment of murine B16F10 melanoma cells promoted activation of melanoma-specific CD8+ T cells and increased the efficacy of a tumor cell vaccine using MQ-treated cells even when the B16F10 cells lacked p53. We then designed a novel combination of APR-246 with the TLR-4 agonist, monophosphoryl lipid A, and a CD40 agonist to further enhance these immunogenic effects and demonstrated a significant antitumor response...
January 2024: Life Science Alliance
https://read.qxmd.com/read/37732411/first-person-profile-jedd-wolchok-md-advances-in-treating-metastatic-melanoma-can-in-part-be-charted-by-the-career-of-dr-wolchok-who-was-on-the-front-lines-of-investigating-immunotherapy-science-and-developed-the-first-immunologic-agents-to-treat-melanoma
#5
https://read.qxmd.com/read/37699333/tumor-dynamics-in-patients-with-solid-tumors-treated-with-pembrolizumab-beyond-disease-progression
#6
JOURNAL ARTICLE
Brian G Topp, Madhav Channavazzala, Kapil Mayawala, Dinesh P De Alwis, Eric Rubin, Alexandra Snyder, Jedd D Wolchok, Antoni Ribas
While many patients are treated beyond progression (TBP), the magnitude and duration of clinical benefit in these patients have not been fully quantified. Data from 799 patients with melanoma (n = 176), non-small cell lung cancer (NSCLC; n = 146), gastric cancer (GC; n = 87), head and neck squamous cell carcinoma (HNSCC; n = 112), clear-cell renal cell carcinoma (ccRCC; n = 51), and urothelial carcinoma (UC; n = 227) TBP were included. Patients had received pembrolizumab beyond confirmed progressive disease (PD) per RECIST v1...
September 11, 2023: Cancer Cell
https://read.qxmd.com/read/37327788/mct4-dependent-lactate-secretion-suppresses-antitumor-immunity-in-lkb1-deficient-lung-adenocarcinoma
#7
JOURNAL ARTICLE
Yu Qian, Ana Galan-Cobo, Irene Guijarro, Minghao Dang, David Molkentine, Alissa Poteete, Fahao Zhang, Qi Wang, Jing Wang, Edwin Parra, Apekshya Panda, Jacy Fang, Ferdinandos Skoulidis, Ignacio I Wistuba, Svena Verma, Taha Merghoub, Jedd D Wolchok, Kwok-Kin Wong, Ralph J DeBerardinis, John D Minna, Natalie I Vokes, Catherine B Meador, Justin F Gainor, Linghua Wang, Alexandre Reuben, John V Heymach
Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the underlying mechanisms remain unelucidated. We find that LKB1 loss results in enhanced lactate production and secretion via the MCT4 transporter. Single-cell RNA profiling of murine models indicates that LKB1-deficient tumors have increased M2 macrophage polarization and hypofunctional T cells, effects that could be recapitulated by the addition of exogenous lactate and abrogated by MCT4 knockdown or therapeutic blockade of the lactate receptor GPR81 expressed on immune cells...
July 10, 2023: Cancer Cell
https://read.qxmd.com/read/37172579/recistv1-1-progression-in-oncology-shades-of-gray
#8
JOURNAL ARTICLE
Brian Topp, Alexandra Snyder, Jedd Wolchok
The Response Evaluation Criteria in Solid Tumors (RECIST)-based outcomes, such as objective response rate (ORR) or progression free survival (PFS), are standard outcomes for early oncology trials. These indices provide a black-and-white interpretation of response to therapy. We propose that lesion-level analysis and mechanism-based pharmacodynamic endpoints may provide a more informative index of response to therapy. Accounting for "shades of gray" in lesion-level response assessments may reduce bias in go/no-go decisions and biomarker analyses for novel oncology compounds and discontinuation decisions for individual patients...
June 12, 2023: Cancer Cell
https://read.qxmd.com/read/37165196/personalized-rna-neoantigen-vaccines-stimulate-t-cells-in-pancreatic-cancer
#9
JOURNAL ARTICLE
Luis A Rojas, Zachary Sethna, Kevin C Soares, Cristina Olcese, Nan Pang, Erin Patterson, Jayon Lihm, Nicholas Ceglia, Pablo Guasp, Alexander Chu, Rebecca Yu, Adrienne Kaya Chandra, Theresa Waters, Jennifer Ruan, Masataka Amisaki, Abderezak Zebboudj, Zagaa Odgerel, George Payne, Evelyna Derhovanessian, Felicitas Müller, Ina Rhee, Mahesh Yadav, Anton Dobrin, Michel Sadelain, Marta Łuksza, Noah Cohen, Laura Tang, Olca Basturk, Mithat Gönen, Seth Katz, Richard Kinh Do, Andrew S Epstein, Parisa Momtaz, Wungki Park, Ryan Sugarman, Anna M Varghese, Elizabeth Won, Avni Desai, Alice C Wei, Michael I D'Angelica, T Peter Kingham, Ira Mellman, Taha Merghoub, Jedd D Wolchok, Ugur Sahin, Özlem Türeci, Benjamin D Greenbaum, William R Jarnagin, Jeffrey Drebin, Eileen M O'Reilly, Vinod P Balachandran
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2,3 . Here in a phase I trial of adjuvant autogene cevumeran, an individualized neoantigen vaccine based on uridine mRNA-lipoplex nanoparticles, we synthesized mRNA neoantigen vaccines in real time from surgically resected PDAC tumours. After surgery, we sequentially administered atezolizumab (an anti-PD-L1 immunotherapy), autogene cevumeran (a maximum of 20 neoantigens per patient) and a modified version of a four-drug chemotherapy regimen (mFOLFIRINOX, comprising folinic acid, fluorouracil, irinotecan and oxaliplatin)...
June 2023: Nature
https://read.qxmd.com/read/37145142/ox40l-expressing-recombinant-modified-vaccinia-virus-ankara-induces-potent-antitumor-immunity-via-reprogramming-tregs
#10
JOURNAL ARTICLE
Ning Yang, Yi Wang, Shuaitong Liu, Shanza Baseer Tariq, Joseph M Luna, Gregory Mazo, Adrian Tan, Tuo Zhang, Jiahu Wang, Wei Yan, John Choi, Anthony Rossi, Jenny Zhaoying Xiang, Charles M Rice, Taha Merghoub, Jedd D Wolchok, Liang Deng
Effective depletion of immune suppressive regulatory T cells (Tregs) in the tumor microenvironment without triggering systemic autoimmunity is an important strategy for cancer immunotherapy. Modified vaccinia virus Ankara (MVA) is a highly attenuated, non-replicative vaccinia virus with a long history of human use. Here, we report rational engineering of an immune-activating recombinant MVA (rMVA, MVA∆E5R-Flt3L-OX40L) with deletion of the vaccinia E5R gene (encoding an inhibitor of the DNA sensor cyclic GMP-AMP synthase, cGAS) and expression of two membrane-anchored transgenes, Flt3L and OX40L...
August 7, 2023: Journal of Experimental Medicine
https://read.qxmd.com/read/37039320/beyond-the-5-year-milestone-long-term-survivorship-of-melanoma-patients-treated-off-trial-with-anti-pd-1
#11
JOURNAL ARTICLE
Kimberly Loo, Hannah L Kalvin, Katherine S Panageas, Margaret K Callahan, Paul B Chapman, Parisa Momtaz, Alexander N Shoushtari, Jedd D Wolchok, Michael A Postow, Allison Betof Warner
Little is known about the long-term outcomes of anti-PD-1 treated patients with melanoma beyond 5 years, especially for patients treated off clinical trials. This retrospective cohort study includes patients with unresectable stage III/IV nonuveal melanoma treated with anti-PD-1 off-trial at Memorial Sloan Kettering Cancer Center between 2014 and 2017 who survived at least 5 years following their first anti-PD-1 dose (N = 139). We characterized overall survival (OS), melanoma-specific survival (MSS) estimates, treatment-free survival rates, and subsequent treatment courses...
April 11, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/37037616/prior-anti-ctla-4-therapy-impacts-molecular-characteristics-associated-with-anti-pd-1-response-in-advanced-melanoma
#12
JOURNAL ARTICLE
Katie M Campbell, Meelad Amouzgar, Shannon M Pfeiffer, Timothy R Howes, Egmidio Medina, Michael Travers, Gabriela Steiner, Jeffrey S Weber, Jedd D Wolchok, James Larkin, F Stephen Hodi, Silvia Boffo, Lisa Salvador, Daniel Tenney, Tracy Tang, Marshall A Thompson, Christine N Spencer, Daniel K Wells, Antoni Ribas
Immune checkpoint inhibitors (ICIs), including CTLA-4- and PD-1-blocking antibodies, can have profound effects on tumor immune cell infiltration that have not been consistent in biopsy series reported to date. Here, we analyze seven molecular datasets of samples from patients with advanced melanoma (N = 514) treated with ICI agents to investigate clinical, genomic, and transcriptomic features of anti-PD-1 response in cutaneous melanoma. We find that prior anti-CTLA-4 therapy is associated with differences in genomic, individual gene, and gene signatures in anti-PD-1 responders...
April 10, 2023: Cancer Cell
https://read.qxmd.com/read/37024582/genomic-and-transcriptomic-analysis-of-checkpoint-blockade-response-in-advanced-non-small-cell-lung-cancer
#13
JOURNAL ARTICLE
Arvind Ravi, Matthew D Hellmann, Monica B Arniella, Mark Holton, Samuel S Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T Griffin, Natalie I Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi, Biagio Ricciuti, Patrick M Forde, Valsamo Anagnostou, Jonathan W Riess, Don L Gibbons, Nathan A Pennell, Vamsidhar Velcheti, Subba R Digumarthy, Mari Mino-Kenudson, Andrea Califano, John V Heymach, Roy S Herbst, Julie R Brahmer, Kurt A Schalper, Victor E Velculescu, Brian S Henick, Naiyer Rizvi, Pasi A Jänne, Mark M Awad, Andrew Chow, Benjamin D Greenbaum, Marta Luksza, Alice T Shaw, Jedd Wolchok, Nir Hacohen, Gad Getz, Justin F Gainor
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade...
May 2023: Nature Genetics
https://read.qxmd.com/read/37001526/lineage-tracing-reveals-clonal-progenitors-and-long-term-persistence-of-tumor-specific-t-cells-during-immune-checkpoint-blockade
#14
JOURNAL ARTICLE
Joy A Pai, Matthew D Hellmann, Jennifer L Sauter, Marissa Mattar, Hira Rizvi, Hyung Jun Woo, Nisargbhai Shah, Evelyn M Nguyen, Fathema Z Uddin, Alvaro Quintanal-Villalonga, Joseph M Chan, Parvathy Manoj, Viola Allaj, Marina K Baine, Umesh K Bhanot, Mala Jain, Irina Linkov, Fanli Meng, David Brown, Jamie E Chaft, Andrew J Plodkowski, Mathieu Gigoux, Helen H Won, Triparna Sen, Daniel K Wells, Mark T A Donoghue, Elisa de Stanchina, Jedd D Wolchok, Brian Loomis, Taha Merghoub, Charles M Rudin, Andrew Chow, Ansuman T Satpathy
Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq analysis of 187,650 T cells from 31 tissue regions, including tumor, adjacent normal tissues, and lymph nodes (LN), from three patients with non-small cell lung cancer after immune checkpoint blockade (ICB). Regions with viable cancer cells are enriched for exhausted CD8+ T cells, regulatory CD4+ T cells (Treg), and follicular helper CD4+ T cells (TFH)...
April 10, 2023: Cancer Cell
https://read.qxmd.com/read/37001503/t-cell-immunotherapies-engage-neutrophils-to-eliminate-tumor-antigen-escape-variants
#15
JOURNAL ARTICLE
Daniel Hirschhorn, Sadna Budhu, Lukas Kraehenbuehl, Mathieu Gigoux, David Schröder, Andrew Chow, Jacob M Ricca, Billel Gasmi, Olivier De Henau, Levi Mark B Mangarin, Yanyun Li, Linda Hamadene, Anne-Laure Flamar, Hyejin Choi, Czrina A Cortez, Cailian Liu, Aliya Holland, Sara Schad, Isabell Schulze, Allison Betof Warner, Travis J Hollmann, Arshi Arora, Katherine S Panageas, Gabrielle A Rizzuto, Rebekka Duhen, Andrew D Weinberg, Christine N Spencer, David Ng, Xue-Yan He, Jean Albrengues, David Redmond, Mikala Egeblad, Jedd D Wolchok, Taha Merghoub
Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple branches of the immune system may eliminate escape variants. Here, we show that melanoma-specific CD4+ T cell therapy in combination with OX40 co-stimulation or CTLA-4 blockade can eradicate melanomas containing antigen escape variants. As expected, early on-target recognition of melanoma antigens by tumor-specific CD4+ T cells was required...
March 30, 2023: Cell
https://read.qxmd.com/read/37000164/eganelisib-a-first-in-class-pi3k-%C3%AE-inhibitor-in-patients-with-advanced-solid-tumors-results-of-the-phase-1-1b-mario-1-trial
#16
JOURNAL ARTICLE
David S Hong, Michael Postow, Bartosz Chmielowski, Ryan Sullivan, Amita Patnaik, Ezra E W Cohen, Geoffrey Shapiro, Conor Steuer, Martin Gutierrez, Heather Yeckes-Rodin, Robert Ilaria, Brenda O'Connell, Joanna Peng, Guangbin Peng, Nora Zizlsperger, Anthony Tolcher, Jedd D Wolchok
PURPOSE: Eganelisib (IPI-549) is a first-in-class, orally administered, highly selective phosphoinositide-3-kinase (PI3K)-γ inhibitor with anti-tumor activity alone and in combination with programmed cell death protein 1/ligand 1 (PD-1/PD-L1) inhibitors in preclinical studies. This phase 1/1b first-in-human, MAcrophage Reprogramming in Immuno-Oncology-1 (MARIO-1; NCT02637531) study evaluated the safety and tolerability of once-daily eganelisib as monotherapy and in combination with nivolumab in patients with solid tumors...
March 31, 2023: Clinical Cancer Research
https://read.qxmd.com/read/36858729/harnessing-imaging-tools-to-guide-immunotherapy-trials-summary-from-the-national-cancer-institute-cancer-imaging-steering-committee-workshop
#17
REVIEW
Lalitha K Shankar, Heiko Schöder, Elad Sharon, Jedd Wolchok, Michael V Knopp, Richard L Wahl, Benjamin M Ellingson, Nathan C Hall, Martin J Yaffe, Alexander J Towbin, Michael D Farwell, Daniel Pryma, Tina Young Poussaint, Chadwick L Wright, Lawrence Schwartz, Mukesh Harisinghani, Umar Mahmood, Anna M Wu, David Leung, Elisabeth G E de Vries, Ying Tang, Gillian Beach, Steven A Reeves
As the immuno-oncology field continues the rapid growth witnessed over the past decade, optimising patient outcomes requires an evolution in the current response-assessment guidelines for phase 2 and 3 immunotherapy clinical trials and clinical care. Additionally, investigational tools-including image analysis of standard-of-care scans (such as CT, magnetic resonance, and PET) with analytics, such as radiomics, functional magnetic resonance agents, and novel molecular-imaging PET agents-offer promising advancements for assessment of immunotherapy...
March 2023: Lancet Oncology
https://read.qxmd.com/read/36745014/decision-making-and-health-related-quality-of-life-in-patients-with-melanoma-considering-adjuvant-immunotherapy
#18
JOURNAL ARTICLE
Thomas M Atkinson, Jennifer L Hay, Soo Young Kim, Elizabeth Schofield, Michael A Postow, Parisa Momtaz, Allison Betof Warner, Alexander N Shoushtari, Margaret K Callahan, Jedd D Wolchok, Yuelin Li, Paul B Chapman
BACKGROUND: Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is associated with risks of immune-related adverse events (irAEs), some permanent. We identified factors patients consider in deciding whether to undergo adjuvant anti-PD1 treatment and assessed prospective health-related quality of life (HRQoL), treatment satisfaction, and decisional regret. PATIENTS AND METHODS: Patients with stage IIIB-IV cutaneous melanoma and free of disease, were candidates for adjuvant anti-PD1 immunotherapy, and had not yet discussed adjuvant treatment options with their oncologist were eligible...
April 6, 2023: Oncologist
https://read.qxmd.com/read/36574773/the-ectonucleotidase-cd39-identifies-tumor-reactive-cd8-t%C3%A2-cells-predictive-of-immune-checkpoint-blockade-efficacy-in-human-lung-cancer
#19
JOURNAL ARTICLE
Andrew Chow, Fathema Z Uddin, Michael Liu, Anton Dobrin, Barzin Y Nabet, Levi Mangarin, Yonit Lavin, Hira Rizvi, Sam E Tischfield, Alvaro Quintanal-Villalonga, Joseph M Chan, Nisargbhai Shah, Viola Allaj, Parvathy Manoj, Marissa Mattar, Maximiliano Meneses, Rebecca Landau, Mariana Ward, Amanda Kulick, Charlene Kwong, Matthew Wierzbicki, Jessica Yavner, Jacklynn Egger, Shweta S Chavan, Abigail Farillas, Aliya Holland, Harsha Sridhar, Metamia Ciampricotti, Daniel Hirschhorn, Xiangnan Guan, Allison L Richards, Glenn Heller, Jorge Mansilla-Soto, Michel Sadelain, Christopher A Klebanoff, Matthew D Hellmann, Triparna Sen, Elisa de Stanchina, Jedd D Wolchok, Taha Merghoub, Charles M Rudin
Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies. CD39 expression is a promising surrogate of tumor-reactive CD8+ T cells. Here, we comprehensively profiled CD39 expression in human lung cancer. CD39 expression enriched for CD8+ T cells with features of exhaustion, tumor reactivity, and clonal expansion. Flow cytometry of 440 lung cancer biospecimens revealed weak association between CD39+ CD8+ T cells and tumoral features, such as programmed death-ligand 1 (PD-L1), tumor mutation burden, and driver mutations...
January 10, 2023: Immunity
https://read.qxmd.com/read/36261460/heat-inactivated-modified-vaccinia-virus-ankara-boosts-th1-cellular-and-humoral-immunity-as-a-vaccine-adjuvant
#20
JOURNAL ARTICLE
Ning Yang, Aitor Garcia, Cindy Meyer, Thomas Tuschl, Taha Merghoub, Jedd D Wolchok, Liang Deng
Protein or peptide-based subunit vaccines have generated excitement and renewed interest in combating human cancer or COVID-19 outbreak. One major concern for subunit vaccine application is the weak immune responses induced by protein or peptides. Developing novel and effective vaccine adjuvants are critical for the success of subunit vaccines. Here we explored the potential of heat-inactivated MVA (heat-iMVA) as a vaccine adjuvant. Heat-iMVA dramatically enhances T cell responses and antibodies responses, mainly toward Th1 immune responses when combined with protein or peptide-based immunogen...
October 19, 2022: NPJ Vaccines
keyword
keyword
105584
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.